AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00338377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrathecal Interleukin-2
Description: 1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated. Then, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks patients switched to IL-2 maintenance.
Study NCT02509845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00735722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIFU AF Ablation
Description: Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)
Study NCT04457063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PKP
Description: 1. The horizontal axis was marked with a pointed marker at the slit lamp immediately before surgery.~2. TICL loading into the STAAR injector cartridge~3. Temporal clear corneal 3 mm incision \& 2-side ports then viscoelastic injection into the AC~4. Implantation of the TICL using the injector, then rotation according to the implantation diagram guided with Mendez protractor, and lastly placement of the haptics under the iris.~5. Pupil constriction with A.Ch.~6. Washing the viscoelastic \&Wound hydration.~7. Topical antibiotic steroids (Vigamox and Tobradex) 4 times /day for 3weeks
Study NCT02645292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 mile walk using treadmill
Description: Walk for 1 mile on treadmill (American Motion Fitness, 8800D) at self selected speed as fast as participant can without any inclination.
Study NCT02645292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stair Climbing
Description: Climb 14 flights of stairs at self selected speed. No double step at a time and running allowed.
Study NCT02798978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.
Study NCT02798978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be supplied as a solution for injection vial and will be administered as IV bolus over 2-5 min followed by a IV bolus of 10 mL normal saline
Study NCT00301418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Tarceva®: Will be given at a starting dose of 150mg QD dose for the first cycle which is 28 days. This will be followed by 14 days of 100mg PO on a bid schedule and 150mg PO on a bid schedule for the final 14 days of the second cycle. Assuming no dose limiting toxicity, 150 mg PO tid will be continued for up to 10 more cycles. This is an outpatient regimen, in which the drug is admininistered orally. Tumor response will be assessed after every 2nd treatment cycle. Patients may receive a maximum of 12 cycles of treatment under this research protocol.
Study NCT00772265 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wosulin N
Description: Total Dose per subject will be 0.4IU/Kg given Subcutaneously.
Study NCT00772265 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novolin N
Description: Total dose per subject will be 0.4 IU/Kg given Subcutaneously.
Study NCT02175979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enriched enteral nutrition
Description: enriched enteral tube feeding perioperative
Study NCT02175979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: standard
Description: standard of care
Study NCT03320980 — intervention group
Intervention type: PROCEDURE
Intervention: RALPPS
Description: RALPPS: split-in-situ resection with radio-frequency ablation (RFA) instead of liver partition on the first stage and major liver resection on the second stage
Study NCT03320980 — intervention group
Intervention type: PROCEDURE
Intervention: portal vein embolization + major liver resection
Description: PVE on the first stage and major liver resection on the second stage
Study NCT03320031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Take linagliptin 5mg a day.
Study NCT03320031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog Mix 75/25
Description: Administer subcutaneous premixed insulin twice a day.
Study NCT03320031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog Mix 75/25
Description: Administer subcutaneous premixed insulin twice a day.
Study NCT03417245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fitusiran
Description: by SC injection
Study NCT03417245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: factor concentrates
Description: by intravenous (IV) injection
Study NCT00544778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00544778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Study NCT00544778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00544778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00544778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00544778 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Study NCT00544778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study NCT00544778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00544778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00544778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00544778 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00118560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: treadmill walking
Study NCT00118560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical walking
Description: calf muscle exercise
Study NCT04096924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guidewire for echo-guided interventions
Description: Under echocardiography guided treatment of ASD with a novel interventional guidewire
Study NCT04096924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook lunderquist guidewire
Description: Subjects with ASD treated with amplatzer using the Cook lunderquist guidewire.
Study NCT02334293 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omegaven
Description: Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.
Study NCT04111913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: anlotinib once daily on days 1-14 of 21days cycle.
Study NCT03679117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: Phone-delivered mindfulness training. 8 weeks of 30 minute phone sessions with an instructor, plus 15 minutes of self-guided practice.
Study NCT03030131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: durvalumab 750 mg IV Day1, 15, 29
Study NCT01220817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 POMx capsules
Description: 3 POMx capsules daily
Study NCT01220817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 POMx capsule
Description: 1 POMx capsule daily
Study NCT00198107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 kg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.
Study NCT00198107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
Study NCT00198107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
Study NCT02672475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Given PO
Study NCT02672475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02672475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02067728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FNPA tool
Description: Intervention practice will train to use FNPA screening paired with Brief Action Planning. They will implement this approach during well child visits.
Study NCT02067728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Practices not undergoing intervention with FNPA tool will provide usual care to patients during well-child visits.
Study NCT03660657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 µg/ml; 40 sessions in 16 weeks.
Study NCT03660657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 µg/ml (only O2); 40 sessions in 16 weeks.
Study NCT04942951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gynecological examination
Description: Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
Study NCT04942951 — intervention group
Intervention type: OTHER
Intervention: Pelvic Organ Prolapse Quantification (POP-Q)
Description: Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
Study NCT04942951 — intervention group
Intervention type: OTHER
Intervention: Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) questionnaire
Description: ICIQ-SF questionnaire was applied to the Study group to determine the severity of urinary incontinence.
Study NCT04942951 — intervention group
Intervention type: OTHER
Intervention: Pregnancy-Related Anxiety Questionnaire-Revised 2 (PRAQ-R2) questionnaire
Description: PRAQ-R2 questionnaire was applied to the whole pregnant cohort included in the study to determine their anxiety status.
Study NCT03495102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC
Study NCT03495102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study NCT00967356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5985
Description: Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits
Study NCT00967356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study NCT01509638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 Standard of Care
Description: Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.
Study NCT01509638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 EXPAREL
Description: Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
Study NCT03166891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: Take 50mg orally once daily
Study NCT00494234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Participants will receive capsules of olaparib orally as stated in arm description.
Study NCT01980056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosaroxin
Description: Dose level 1: Vosaroxin 50 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg\^m2 IV on Days 1, 4, 8 and 11 of 28 day cycle
Study NCT01273246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100U inactivated Enterovirus Type 71 Vaccine
Description: Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
Study NCT01273246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 200U inactivated Enterovirus Type 71 Vaccine
Description: Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
Study NCT01273246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 400U inactivated Enterovirus Type 71 Vaccine
Description: Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
Study NCT01273246 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
Study NCT03260621 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: stress CMR
Description: additional stress CMR to the established clinical diagnostics
Study NCT03879824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secondary Radial Artery Access
Description: Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the right radial artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
Study NCT03879824 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Secondary Femoral Artery Access
Description: Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the contralateral femoral artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
Study NCT02012751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nevus doctor program
Description: The Nevus doctor program supplies a diagnostic category of pigmented skin lesions based on dermatoscopy images.
Study NCT03132610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: andrographolide sulfonate
Description: Conventional Therapy+Xiyanping injection
Study NCT03132610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: andrographolide sulfonate simulation
Description: Conventional Therapy+Xiyanping injection simulation
Study NCT02272569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STARflo Glaucoma Implant
Description: Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotic medications.
Study NCT02888782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Consultation
Study NCT02190604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule- oral dose
Study NCT02190604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose
Study NCT01307540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phototherapy
Description: low level light therapy, broad band light wavelengths.
Study NCT04402723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: In first 28-days-cycle, eligible subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination with Daunorubicin 60mg/m2/d, for first 3 days, and Cytarabine 100mg/m2/d, for first 7 days. If CR or CRi is observed, subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination Cytarabine 2g/m2/q12h, for first 3 days, in next 28-day-cycle.
Study NCT02527785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Irinotecan, S-1(OIS)
Description: Treatment will be delivered every 2 weeks~1. oxaliplatin 65 mg/m2 iv on day 1~2. irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day po on day 1-7
Study NCT03127176 — intervention group
Intervention type: OTHER
Intervention: Genome sequencing of fecal samples
Description: Fecal samples will be collected and then frozen in the morning pre-prandial after having fasted overnight. DNA will be separated and stored at -80°C in our center (Biobanc) until assayed. Sequencing will be performed with the most appropriate platform.
Study NCT03742583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Square Knot
Description: Standard square knot
Study NCT03742583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RHAP Knot
Description: Reversing half-hitch alternating post knot
Study NCT04373005 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal (NP) swab
Description: A dry swab will be inserted through one nostril straight towards the back of the nasal passage and rotated gently before the swab is removed.
Study NCT04141423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tregopil
Description: Insulin Tregopil is recombinant human insulin modified by a single amphiphilic oligomer covalently linked via an amide bond to lysine at position 29 of the B-chain. This alters the physicochemical characteristics of the molecule, leading to enhanced stability and resistance to intestinal degradation following oral administration.
Study NCT01307540 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: phototherapy
Description: low level light therapy, broad band light wavelengths.
Study NCT02342899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient NIV Set Up using AVAPS AE (Manufactured by Philips-Respironics)
Description: Intervention set ups will follow a standard protocol for the automated device (A40 AVAPS-AE machine;Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) and patients will be discharged with the machine and a full face mask or nasal interface. Patients will then undergo a 1-2 night home oximetry study to ensure adequate control of overnight oxygenation. Patients will be reviewed clinically as an outpatient at 6 weeks and adherence to non-invasive ventilation will be evaluated and an arterial blood gas measurement will be undertaken. A full clinical review and optimisation of NIV and interface will be performed at this visit. Patients will be reviewed at 3 months as an inpatient where overnight transcutaneous carbon dioxide level and SpO2 studies will be performed. All other patient-centred, physician-centred and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
Study NCT02611908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Cohort 1 420 mg PO daily Cohort 2 560 mg PO daily Cohort 3 700 mg PO daily Cohort 4 840 mg PO daily
Study NCT02611908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: obinutuzumab 100 mg IV on day 1, 900mg IV on day 2, 1000mg IV day 8, 15, 28 then q 28 days for a total of 8 doses.
Study NCT02342899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient NIV Set Up using spontaneous/timed (S/T) mode pressure support ventilation (Manufactured by Philips-Respironics)
Description: The patient will follow a specialist nurse-led protocolised set up of spontaneous/timed (S/T) mode pressure support ventilation (A40 AVAPS-AE machine; Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) using limited respiratory polygraphy, including overnight TcCO2 (Trascutaneous Carbon Dioxide) and SpO2 (Oxygen Saturation) studies. Following the inpatient set-up, patients will be reviewed as an outpatient at 6 weeks and adherence with non-invasive ventilation will be evaluated and arterial blood gas measurements will be performed. Patients will then be reviewed at 3 months as an inpatient where overnight respiratory polygraphy, TcCO2 and SpO2 studies will be repeated. All other patient-centred, physician-centred measurements and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
Study NCT01684319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Formula milk free of cow's milk protein
Study NCT01684319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infant formula milk
Study NCT05649761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1604 injection
Description: Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.